The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 350:2306-2308 May 27, 2004 Number 22
NextNext

Alendronate versus Calcitriol for Prevention of Bone Loss after Cardiac Transplantation

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Lindsay, R.
-Related Article
by Shane, E.
-PubMed Citation
To the Editor: Shane et al. (Feb. 19 issue)1 found minimal differences between the benefits conferred by alendronate and those conferred by calcitriol, and the authors speculated (as did Lindsay, in an accompanying Perspective article2) that combination therapy might improve the response. There is good evidence in the literature on postmenopausal osteoporosis of a synergistic effect when calcitriol is used in combination with an antiresorptive agent (a bisphosphonate or estrogen), as shown in studies of calcitriol combined with cyclical etidronate,3 with alendronate,4 or with estrogen.5,6 The two studies of estrogen both showed significant benefits of the combination, as compared . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.